Wednesday, June 21, 2017 9:03:54 PM
You seemingly haven't analyzed the DSM & Co offerings.
Post tranche-a _and_ b, company may have received about $280.90M fully diluted, which brings equity from $(212.19M) to $68.71M.
This includes the cash warrants naturally.
This assumes a floor price of $6.30 per share, at least for tranche-a and the second tranche also targets the same price as stated in the proxy material.
The anti-dilutive warrants haven't been triggered, allowing a sub $6.30 share price.
Found this sensible analysis of the tranche-a deal RS adjusted:
.. and the corresponding fundamentals, see below.
Well, that is a heck of dilution, however, they are paying a good price for it, 132% premium as of today!
In the end it is clear that they takeover the company. Old shareholder far above $9 may not recover this year, but the transaction surely fixes company's balance sheet and removes all BK risks completely.
At the current price, this seems to be a very bullish case.
Yes, the whole transaction still needs to settle, voting is on 7/7 for AMRS for conversion and tranche-b. DSM also needs to sign for the tranche-b. Also company then needs to produce the positive cash flow in 2018, but w/ DSM this shall be no issue.
A short term bounce is the least possible right now, knowing company just became listing compliant again and had a double bottom.
Recent AMRSQ News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:39 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 02/10/2024 02:24:29 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/10/2024 02:14:56 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:42:49 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/14/2023 09:34:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 10:23:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:43:26 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM